The Contribution of Dostarlimab to First-Line Treatment of Advanced or Recurrent Endometrial Cancer in Spain: A Multi-Criteria Decision Analysis Approach.
- DOI
- 10.3390/jcm15155808
- Published
- 2026 Jul 24
- Container
- Journal of clinical medicine
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3390/jcm15155808,
title = {The Contribution of Dostarlimab to First-Line Treatment of Advanced or Recurrent Endometrial Cancer in Spain: A Multi-Criteria Decision Analysis Approach.},
author = {Barretina-Ginesta MP and Lorente CM and Maximiano C and Díez R and Ec-McDa Group and Ariznavarreta A and Calvo A and Soler F},
year = {2026},
journal = {Journal of clinical medicine},
doi = {10.3390/jcm15155808},
url = {https://doi.org/10.3390/jcm15155808}
}RIS
TY - JOUR TI - The Contribution of Dostarlimab to First-Line Treatment of Advanced or Recurrent Endometrial Cancer in Spain: A Multi-Criteria Decision Analysis Approach. AU - Barretina-Ginesta MP AU - Lorente CM AU - Maximiano C AU - Díez R AU - Ec-McDa Group AU - Ariznavarreta A AU - Calvo A AU - Soler F PY - 2026 JO - Journal of clinical medicine DO - 10.3390/jcm15155808 UR - https://doi.org/10.3390/jcm15155808 ER -
APA
MP, B., CM, L., C, M., R, D., Group, E., A, A., A, C., & F, S. (2026). The Contribution of Dostarlimab to First-Line Treatment of Advanced or Recurrent Endometrial Cancer in Spain: A Multi-Criteria Decision Analysis Approach.. Journal of clinical medicine. https://doi.org/10.3390/jcm15155808
Source records
- pubmed · retrieved 2026-09-25T19:44:50.506Z
- europe-pmc · retrieved 2026-09-25T19:44:50.531Z